Want to see HK:2235 full AI Analyst Report?
2235 Stock Chart & Stats
HK$7.10
-HK$0.10(-1.77%)
At close: 4:00 PM EST
HK$7.10
-HK$0.10(-1.77%)
Day’s Range― - ―
52-Week RangeHK$5.70 - HK$9.17
Previous CloseN/A
Volume41.60K
Average Volume (3M)340.61K
Market Cap
HK$3.05B
Enterprise ValueHK$1.34K
Total Cash (Recent Filing)HK$1.55B
Total Debt (Recent Filing)HK$91.37M
Price to Earnings (P/E)30.3
Beta0.35
Next Earnings
Mar 31, 2027EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.11
Shares Outstanding169,175,840
10 Day Avg. Volume114,320
30 Day Avg. Volume340,611
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)1.42
Price to Sales (P/S)4.33
P/FCF Ratio-468.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.2
Revenue Forecast (FY)HK$910.15M
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue GrowthSustained +101% revenue growth in 2025 indicates durable product adoption and expanding market penetration in diabetes devices. Growth supports scale economies, enlarges the recurring consumables base, and provides room to invest in distribution and R&D over the next 2–6 months and beyond.
High, Stable Gross MarginsA consistent ~53% gross margin shows structural pricing power and favorable product economics common in device plus consumables models. Stable unit economics support margin sustainability as revenue scales, enabling long-term operating leverage once fixed costs are absorbed.
Conservative Balance SheetVery low leverage (debt/equity ~0.05) gives the company financial flexibility to fund commercialization, clinical/regulatory work, or product development without heavy refinancing risk. This conservatism reduces distress probability during investment cycles.
Bears Say
Negative Free Cash FlowPersistently negative free cash flow (-6.1M in 2025) implies ongoing capital intensity or working-capital strain despite revenue growth. That limits self-funded expansion, may require external financing, and constrains durability of returns until FCF turns sustainably positive.
Operating Profitability Not Fully ProvenNegative EBIT/EBITDA despite a return to net income suggests core operating margins and cash profitability are not yet firmly established. Reliance on non-operating items or one-offs could leave earnings vulnerable unless operational cost structure improves with scale.
Low Returns On CapitalROE of ~1.9% indicates deployed capital is generating limited returns relative to peers. For a capital-intensive medical-device rollout, low returns slow the company’s ability to self-finance growth and may require better margin capture or higher asset efficiency to be durable.
MicroTech Medical (Hangzhou) Co., Ltd. Class H News
2235 FAQ
What was MicroTech Medical (Hangzhou) Co., Ltd. Class H’s price range in the past 12 months?
MicroTech Medical (Hangzhou) Co., Ltd. Class H lowest stock price was HK$5.70 and its highest was HK$9.17 in the past 12 months.
What is MicroTech Medical (Hangzhou) Co., Ltd. Class H’s market cap?
MicroTech Medical (Hangzhou) Co., Ltd. Class H’s market cap is HK$3.05B.
When is MicroTech Medical (Hangzhou) Co., Ltd. Class H’s upcoming earnings report date?
MicroTech Medical (Hangzhou) Co., Ltd. Class H’s upcoming earnings report date is Mar 31, 2027 which is in 216 days.
How were MicroTech Medical (Hangzhou) Co., Ltd. Class H’s earnings last quarter?
MicroTech Medical (Hangzhou) Co., Ltd. Class H released its earnings results on Aug 21, 2026. The company reported HK$0.117 earnings per share for the quarter, beating the consensus estimate of HK$0.093 by HK$0.023.
Is MicroTech Medical (Hangzhou) Co., Ltd. Class H overvalued?
According to Wall Street analysts MicroTech Medical (Hangzhou) Co., Ltd. Class H’s price is currently Overvalued.
Does MicroTech Medical (Hangzhou) Co., Ltd. Class H pay dividends?
MicroTech Medical (Hangzhou) Co., Ltd. Class H does not currently pay dividends.
What is MicroTech Medical (Hangzhou) Co., Ltd. Class H’s EPS estimate?
MicroTech Medical (Hangzhou) Co., Ltd. Class H’s EPS estimate is 0.15.
How many shares outstanding does MicroTech Medical (Hangzhou) Co., Ltd. Class H have?
MicroTech Medical (Hangzhou) Co., Ltd. Class H has 169,175,840 shares outstanding.
What happened to MicroTech Medical (Hangzhou) Co., Ltd. Class H’s price movement after its last earnings report?
MicroTech Medical (Hangzhou) Co., Ltd. Class H reported an EPS of HK$0.117 in its last earnings report, beating expectations of HK$0.093. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MicroTech Medical (Hangzhou) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2235
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MicroTech Medical (Hangzhou) Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.66%
Trailing 12-Months
Company Description
MicroTech Medical (Hangzhou) Co., Ltd. Class H
MicroTech Medical (Hangzhou) Co., Ltd. focuses on the innovation, production, and market distribution of essential medical devices and consumables for diabetes management. Its operations extend across the People's Republic of China and into global markets. The company offers a comprehensive range of products, including the Equil Patch insulin pump systems, AiDEX continuous glucose monitoring systems, POCT analyzer systems, traditional blood glucose monitoring systems, and advanced closed-loop artificial pancreas technology. Beyond its core offerings, MicroTech Medical is also actively involved in engineering and technological research, experimentation, and developmental endeavors. The firm, established in 2011, maintains its headquarters in Hangzhou, People's Republic of China.
Technical Analysis
MicroPort Scientific
―
Peijia Medical Ltd.
―
LifeTech Scientific Corporation
―
Vincent Medical Holdings Limited
―
MicroPort CardioFlow Medtech Corp.
―